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Gene therapyIn human adenoviruses (HAdV), 240 copies of the 14.3-kDaminor capsid protein IX stabilize the capsid. Three
N-terminal domains of protein IX form triskelions between hexon capsomers. The C-terminal domains of four
protein IX monomers associate near the facet periphery. The precise biological role of protein IX remains
enigmatic. Here we show that deletion of the protein IX gene from a HAdV-5 vector enhanced the reporter
gene delivery 5 to 25-fold, speciﬁcally to Coxsackie and Adenovirus Receptor (CAR)-negative cell lines.
Deletion of the protein IX gene also resulted in enhanced activation of peripheral blood mononuclear cells.
The mechanism for the enhanced transduction is obscure. No differences in ﬁber loading, integrin-
dependency of transduction, or factor-X binding could be established between protein IX-containing and
protein IX-deﬁcient particles. Our data suggest that protein IX can affect the cell tropism of HAdV-5, and may
function to dampen the innate immune responses against HAdV particles.ell Biology, Leiden University
Leiden, The Netherlands. Fax:
vier OA license.© 2010 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Protein IX is a non-essential protein in the capsid of human
adenoviruses (HAdV). The protein has a size of 14.3 kDa, is present at
240 copies per virion, and has three highly conserved regions present in
the amino (N) terminus, the central part (alanine-rich), and the carboxy
(C) terminus (leucine-rich). The location and function of protein IX in
the virus capsid has been the subject of investigation and debate for
many years (Vellinga et al., 2005b). Recentwork by different groups has
brought consensus on its location and topology in the capsid (Fabry et
al., 2009; Saban et al., 2006). The N-terminus of the protein is located in
between hexon cavities of the groups of nine (GON) hexons,
presumably stabilizing the GONs. The C-terminus of the protein forms
an alpha helix and is exposed on the capsid surface in close contactwith
hexon hypervariable region 4 (HVR4) (Saban et al., 2006). C-terminal
domains of three protein IXmolecules associate in a parallel orientation,
whereas a fourth domain binds in an antiparallel orientation (Fabry et
al., 2009). The role of protein IX in the capsid remains enigmatic. In vitro
analysis revealed the N-terminus of protein IX to confer a thermostablephenotype on HAdV-5 capsids (Vellinga et al., 2005a). Propagation of
protein IXgenedeletedHAdV-5 in cell culture yieldswild-type like virus
titers, demonstrating that protein IX is dispensable for virus replication
in vitro.
Protein IX has potential as an anchor for the attachment of different
types of polypeptides to the viral capsid. Targeting of HAdV-5 to tumor
cells has been achieved by genetically fusing protein IX to a single-chain
T cell receptor directed against MHC class I in complex with MAGE-A1
peptides (de Vrij et al., 2008). Similarly, integrin-binding arginine–
glycine–aspartate (RGD) peptides, as well as single-chain antibody
fragments have been incorporated in this way (Vellinga et al., 2007,
2004). Alternatively, targeting ligands can be coupled to protein IX via
the genetic inclusion of cysteine residues and subsequent chemical
coupling of ligands to the reactive thiol groups (Corjon et al., 2008).
Multiple polypeptides can be incorporated simultaneously (Tang et al.,
2009). A triple-mosaic HAdV-5 vectorwas developedwith a poly-lysine
motif, the herpes simplex virus type 1 (HSV-1) thymidine kinase, and
the monomeric red ﬂuorescent protein fused with protein IX, thereby
combining targeting, therapeutic, and imaging modalities. Recently, it
was demonstrated that HAdV-5 vaccine vectors with pathogen-speciﬁc
antigens fused topIX can stimulate robust protective immune responses
in animals, suggesting a new route for the development of improved
HAdV-5 based recombinant vaccines (Bayer et al., 2010; Boyer et al.,
2010).
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negative cell lines as a result of protein IX-gene deletion from a
HAdV-5-based vector. Furthermore, the protein IX-deﬁcient particles
demonstrated enhanced activation of peripheral blood mononuclear
cells (PBMCs), and had a different in vivo distribution after
intravenous delivery in a mouse model. The exact molecular
mechanism behind this ‘ΔpIX effect’ remains to be delineated. Our
data suggest that protein IX can affect the cell tropism of HAdV-5,
and may function to dampen the innate immune responses against
HAdV particles.
Results
Enhanced transgene expression in CAR-negative cells with Ad5ΔE1ΔpIX
To study the role of protein IX in the HAdV-5 transduction of cells,
we compared the vectors Ad5ΔE1+pIX and Ad5ΔE1ΔpIX for
luciferase transgene expression in a panel of cell lines (Fig. 1A). Cell
lines with varying expression levels of CAR were included (Fig. 1B).
Whereas similar expression levels were obtained with both vectors in
the CAR-positive cell lines HeLa, A549, and MEL2A, the vector
Ad5ΔE1ΔpIX yielded higher levels than Ad5ΔE1+pIX in the CAR-
negative cell lines MZ2-MEL3.0 and VH10. Since these results
suggested a speciﬁc role of the protein IX lacking vector in mediating
relatively higher transduction in the absence of CAR, Ad5ΔE1+pIX
and Ad5ΔE1ΔpIX were analyzed for reporter gene expression in MZ2-
MEL3.0 cells versus MZ2-MEL3.0/CAR cells (Fig. 2B). MZ2-MEL3.0/
CAR cells stably expressed CAR via transduction with a recombinant
lentivirus, which was conﬁrmed by ﬂow cytometry and immune-
ﬂuorescence staining (Fig. 2A). In MZ2-MEL3.0 cells the reporter gene
expression upon infection with Ad5ΔE1ΔpIX was found to be ten-fold
increased compared to infection with Ad5ΔE1+pIX, while in MZ2-
MEL3.0/CAR cells the difference was a mere two-fold (Fig. 2B). The
enhanced transgene expression for Ad5ΔE1ΔpIX on the CAR-negative
cell lineMZ2-MEL3.0 appeared to be not affected by the establishment
of protein IX expression in the cells (by using the recombinant
lentivirus LV-CMV-pIX-IRES-NPTII; Vellinga et al., 2006) prior to the
transduction) (result not shown).
As a next step, the involvement of the C-terminal region of protein
IX in the observed phenomenonwas investigated. This domain, which
is rich in leucine amino acids and is exposed on the HAdV-5 capsid asFig. 1. (A) Transduction of CAR-positive and CAR-negative cells with the replication-deﬁcien
luciferase expression was measured as indicated by the relative luciferase units (RLU) (NS si
(B) Flow cytometry with anti-CAR antibody and PE-labeled secondary antibody to analyze c
incubation with secondary antibody only.an alpha-helical structure (Fabry et al., 2009; Saban et al., 2006), is
highly conserved in human adenoviruses. The biological function of
this conserved domain of protein IX is unknown. We analyzed the
vector Ad5ΔE1pIXΔLEU, which lacks a major part of the C-terminal
region of protein IX (amino acids 100 to 114) for reporter gene
expression in MZ2-MEL3.0 and MZ2-MEL3.0/CAR. Ad5ΔE1pIXΔLEU
demonstrated enhanced transduction of the CAR-negative cell line,
very similar to the Ad5ΔE1ΔpIX vector (Fig. 2C).
To assess the appearance of the vector particles and to check for
the absence of microaggregation, electron microscopy was performed
on Ad5ΔE1+pIX and Ad5ΔE1ΔpIX vector batches. This showed
identically shaped virus particles (Fig. 3A). No signs of microaggrega-
tion were observed. The Ad5ΔE1ΔpIX stock appeared to contain more
small particulate matter, possibly virus debris. As previously de-
scribed, pIX-deﬁcient HAdV-5 particles have an enhanced tendency to
partly dissociate into ﬁber- and penton base-lacking particles (Fabry
et al., 2005). However, our vectors had similar capsid incorporation
levels of ﬁber and hexon proteins, as evident from immunoblot
analyses (Fig. 3B), thus ruling out differences in particle dissociation
for the vector preparations.
Transduction with Ad5ΔE1ΔpIX is integrin-dependent
Wild-type HAdV-5 enters cells via high afﬁnity binding of the
ﬁber knob domain to CAR (Bergelson et al., 1997). Subsequently
low afﬁnity interaction of the penton base with cellular integrins
αVβ3 and αVβ5 promotes virus internalization in clathrin-coated
pits (Nemerow and Stewart, 1999; Wickham et al., 1993). To
answer the question if Ad5ΔE1ΔpIX still uses integrins for cellular
uptake, we analyzed Ad5ΔE1+pIX and Ad5ΔE1ΔpIX for transgene
expression (GFP) in the presence or absence of bivalent cations,
which are necessary for integrin-mediated uptake of wild-type
HAdV-5 into cells (Wickham et al., 1993) (Fig. 4A). This
experiment again displayed a stronger reporter gene expression
of Ad5ΔE1ΔpIX in MZ2-MEL3.0 cells compared to Ad5ΔE1+pIX.
For both vectors the transduction appeared to be totally dependent
on the presence of bivalent cations, with a complete reduction to
background GFP levels for the cation-negative incubation. This is
consistent with integrin-mediated uptake for both vectors. More
speciﬁcally, the integrin-dependency of Ad5ΔE1ΔpIX was con-
ﬁrmed by a small but signiﬁcant (approximately two-fold)t vectors Ad5ΔE1+pIX and Ad5ΔE1ΔpIX. At 24 h post transduction (at 10 pp/cell) the
gniﬁes Not Signiﬁcant, *pb0.02 versus Ad5ΔE1+pIX). Error bars represent SEM (n=3).
ell surface expression level of CAR (white histograms). The gray histograms represent
Fig. 2. Transduction assays on MZ2-MEL3.0 and MZ2-MEL3.0/CAR (A) Detection of CAR expression in MZ2-MEL3.0 cells by immune-ﬂuorescence staining with anti-CAR antibody
and FITC-labeled secondary antibody. The insets represent ﬂow cytometry histograms after staining with anti-CAR antibody and PE-labeled secondary antibody. (B) Luciferase
expression in MZ2-MEL3.0 and MZ2-MEL3.0/CAR after Ad5ΔE1+pIX and Ad5ΔE1ΔpIX transduction. Error bars represent SEM (n=3). (C) Fold enhancement of MZ2-MEL3.0
transduction with Ad5ΔE1ΔpIX and Ad5ΔE1pIXΔLEU as compared to the transduction with Ad5ΔE1+pIX. The fold enhancements are normalized to the vector transduction ratios on
MZ2-MEL3.0/CAR (*pb0.05, **pb0.005 versus Ad5ΔE1+pIX). Errors bars represent SEM (n=3).
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antibodies directed against αVβ3 and αVβ5 integrins (Fig. 4B).
Similar antibody-blocking (1.5-fold reduced transduction for anti-
αVβ3 and anti-αVβ5) was observed for Ad5ΔE1+pIX. Incubating
the cells with higher concentrations of antibodies did not result in
further reductions in transduction levels (data not shown). Anti-
integrin-mediated blocking of transduction was also observed on
A549 cells (Fig. 4B). From these data we conclude that the vectorFig. 3. (A) Electron microscopy on Ad5ΔE1+pIX and Ad5ΔE1ΔpIX samples with negative
Ad5ΔE1+pIX and Ad5ΔE1ΔpIX lysates to analyze capsid incorporation levels of protein IX,Ad5ΔE1ΔpIX still uses integrins for cell internalization in CAR-
deﬁcient cells.
Reduced virus spread of the replication-competent virus Ad5ΔpIX
Our data from the comparative transduction analysis suggest an
alternative interaction of HAdV-5 particles lacking protein IX with the
cell surface. In parallel to cell tropism extending capsid modiﬁcationsstaining of the vector particles in phosphotungstic acid. (B) Immunoblot detection on
hexon, and ﬁber proteins.
Fig. 4. The effect of integrin blocking on transduction of cells with Ad5ΔE1+pIX and Ad5ΔE1ΔpIX. (A) MZ2-MEL3.0 cells were treated with EDTA to remove bivalent cations
necessary for HAdV-5 interaction with integrins. Subsequent transduction was performed in the presence (PBS++) or absence (PBS) of bivalent cations and GFP expression was
measured, as indicated by the mean ﬂuorescence intensity (MFI). Error bars represent SEM (n=3). (B) Vector mediated luciferase expression in MZ2-MEL3.0 and A549 cells in the
presence or absence of antibodies directed against αVβ3 or αVβ5 integrins in the infection medium (*pb0.05 versus control treatment). Error bars represent SEM (n=3).
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protein IX deletion from a replication-competent HAdV-5 virus would
result in a modiﬁed ability to spread in monolayer cell cultures. To
investigate this, we constructed the replication-competent HAdV-5
viruses Ad5+pIX and Ad5ΔpIX. Both viruses expressed GFP, allowing
accurate measurement of plaque size. On A549 cells the plaque size
for the Ad5ΔpIX virus (median 30 arbitrary surface units (ASU), range
20–170) appeared to be signiﬁcantly smaller than the plaque size for
Ad5+E1+pIX (median 100 ASU, range 30–290). A similar difference
in plaque size was observed on the CAR-negative cell line VH10, with
Ad5ΔpIX (median 50 ASU, range 30–150) yielding much smaller
plaques compared to Ad5+pIX (median 100 ASU, range 75–280).Fig. 5. Activation of peripheral blood mononuclear cells (PBMCs) after incubation with Ad5Δ
graphs on the left show the percentage of CD86 positive cells and the mean CD86 expression
the CD86 up-regulation for transduced (GFP-positive) monocytes and non-transduced (GF
percentage of CD69 positive cells and the mean CD69 expression levels (MFI) are shown for
single donor) after incubation with Ad5ΔE1+pIX and Ad5ΔE1ΔpIX. The data represent meFrom these analyses we conclude that protein IX-gene deletion from
the genome of the replication-competent virus results in a decrease in
virus spread in CAR-positive (A549) as well as CAR-negative (VH10)
monolayer cell cultures.
Enhanced activation of peripheral blood mononuclear cells
by Ad5ΔE1ΔpIX
Our ﬁndings on the modiﬁed transduction characteristics of
protein IX-deﬁcient HAdV-5 vectors are of relevance for: (1)
fundamental adeno-virology (as the ﬁndings point towards a novel
biological function of protein IX), and (2) the development of proteinE1+pIX and Ad5ΔE1ΔpIX for two days. (A) Activation of the monocyte population. The
levels (MFI) for three different donors. The ﬂow cytometry ﬁgures on the right illustrate
P-negative) monocytes (from donor 1). (B) Activation of the NK cell population. The
three different donors. (C) Measurement of IFN-γ levels in PBMC supernatant (from a
an values of two independent measurements.
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aspects, it will be highly interesting to determine the effect of protein
IX-deletion on the interaction of HAdV-5 vectors with white blood
cells. Therefore, we incubated freshly isolated human peripheral
blood mononuclear cells with Ad5ΔE1+pIX and Ad5ΔE1ΔpIX, and
analyzed GFP expression and the expression of cellular activation
markers. This revealed relatively high levels of GFP expression in the
monocyte population. The percentage of GFP-positive monocytes was
similar for both vectors, varying between 10% and 30% at 100 pp/cell,
depending on the donor (data not shown). For both vectors the GFP
expression in the T cell, B cell, and NK cell populations was very low
(b1% GFP-positive cells). Although Ad5ΔE1+pIX and Ad5ΔE1ΔpIX
showed identical GFP expression levels in the monocytes, the
incubation with Ad5ΔE1ΔpIX resulted in a remarkably higher level
of monocyte activation, as indicated by enhanced CD86 expression
(Fig. 5A). The percentage of CD86 positive monocytes as well as the
mean ﬂuorescence intensity for CD86 was signiﬁcantly higher for the
pIX-lacking vector. This enhancement in monocyte activation was
observed for monocytes derived from PBMCs of three different donors
and with different virus batches. The up-regulated CD86 level
involved the entire Ad5ΔE1ΔpIX-incubated monocyte population,
not only the GFP-positive cells (Fig. 5A). Incubation with Ad5ΔE1ΔpIX
also resulted in enhanced activation of NK cells, as demonstrated by
an increase in CD69 expression (Fig. 5B). Interferon-gamma (IFN-γ)
ELISA of PBMC supernatants revealed higher levels of IFN-γ
production after incubation with Ad5ΔE1ΔpIX at the higher input
virus levels (Fig. 5C).Enhanced liver transduction upon intravenous administration
of Ad5ΔpIX
To study the functional consequences of protein IX-gene deletion
on biodistribution in mice, Ad5ΔE1+pIX and Ad5ΔE1ΔpIX viruses
were administered via tail vein injection. Luciferase expression in
multiple organs was determined at 3 days post injection. The vector
lacking protein IX yielded a more than ten-fold higher luciferase
activity in the liver (Fig. 6A). These data show that the absence ofFig. 6. (A) Distribution of Ad5ΔE1+pIX and Ad5ΔE1ΔpIX in mice after tail vein injection of 1
HAdV-5.CMV to saturate Kupffer cell macrophages. Organs were harvested three days pos
**p=0.006 versus Ad5ΔE1+pIX). Error bars represent SEM (n=2). (B) Luciferase expressio
presence of coagulation factor X (FX), Gla-domainless mutant factor X (FXMUT), or no coagprotein IX in the viral capsid strongly affected the biodistribution of
HAdV-5 particles.
Recent reports have described the involvement of plasma
proteins, such as the blood coagulation factor X (FX), in HAdV-5
transduction of the liver (Kalyuzhniy et al., 2008; Waddington et al.,
2008). To study whether removal of protein IX inﬂuences the effects
of clotting-factor binding we compared the FX-mediated transduc-
tion for Ad5ΔE1+pIX and Ad5ΔE1ΔpIX (Fig. 6B). In vitro incubation
of A549 cells and HepG2 cells with FX resulted in a similar
enhancement in transduction for Ad5+pIX and Ad5ΔpIX. As
expected, no effect on transduction was observed after incubation
with the mutant FX (FXMUT), which lacks the domain necessary for
binding to the HAdV-5 capsid (Waddington et al., 2008). From these
data we conclude that the absence of protein IX does not affect the
binding of coagulation factor X.
Discussion
From our data we conclude that the omission of protein IX from
HAdV-5 vectors enhances viral transduction of cell lines that are low
in expression of the adenovirus receptor CAR. This ﬁnding is of
relevance for the development and implementation of protein IX-
gene modiﬁed HAdV-5 vectors. Also, the ﬁndings enhance our
knowledge on HAdV-5 biology and evolution, which especially
becomes clear if stating our conclusion in a ‘backwards’ manner: the
introduction of protein IX in HAdV-5 (making it wild-type HAdV-5)
decreases viral transduction of cell lines that are low in CAR
expression. Although speculative, it is very well possible that the
presence of protein IX in the HAdV-5 capsid negatively interferes with
non-speciﬁc cell transduction, and thereby plays a role in determining
the virus tropism. Noteworthy, the extended cell tropism of the
Ad5ΔE1ΔpIX vector, as presented by its enhanced transduction of
CAR-negative cells, did not come with a loss in ability of CAR-
mediated transduction of cells. This is clear from the comparison on
MZ2-MEL3.0 and MZ2-MEL3.0/CAR. Introduction of CAR in the CAR-
negative cells signiﬁcantly increased transduction levels with
Ad5ΔE1ΔpIX. It is conceivable that in CAR-expressing cells the protein
IX-deﬁcient particles can use either the CAR/ﬁber-dependent09 vector particles. Prior to vector injection, pre-dosing was performed with the vector
t injection and the luciferase expression per total protein was measured (*p=0.057,
n in HepG2 and A549 cells after transduction with Ad5ΔE1+pIX and Ad5ΔE1ΔpIX in the
ulation factors (mock). Error bars represent SEM (n=3).
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Quantifying the relative contribution of each of these mechanisms to
the total transduction requires tools for speciﬁcally blocking the new
pathway. Such inhibitors remain to be identiﬁed.
Interestingly, the vector Ad5ΔE1pIXΔLEU had Ad5ΔE1ΔpIX-like
properties, implicating the importance of the C-terminal domain of
protein IX in inhibiting transgene expression in CAR-negative cell
lines. The speciﬁcity for the C-terminal domain of protein IX excludes
differences in viral capsid stability as a cause for the observed
phenomenon, since deletion of this domain does not result in reduced
capsid stability (Vellinga et al., 2005a).
Wild-type HAdV-5 enters cells via high afﬁnity binding of the ﬁber
knob domain to CAR (Bergelson et al., 1997), followed by interaction
of the RGD motif of the penton base with cellular integrins αVβ3 and
αVβ5 promoting rapid adenovirus cell entry into clathrin-coated
vesicles (Nemerow and Stewart, 1999; Wickham et al., 1993). Similar
to the Ad5ΔE1+pIX control virus, Ad5ΔE1ΔpIX requires the presence
of bivalent cations for its transgene delivery, indicating the usage of
cellular integrins for cell internalization (Wickham et al., 1993). More
speciﬁcally, blocking cells with anti-integrin antibodies resulted in a
decrease in transduction for Ad5ΔE1ΔpIX, thereby conﬁrming the
integrin-dependency. Unfortunately, our efforts to compare the
vectors for a general difference in cell-binding afﬁnity, using
Alexa488-TFP (tetraﬂuorophenyl) labeled vector particles, were not
conclusive as a result of strong and reproducible negative effects of
the labeling procedure on the pIX-deﬁcient vector particles. The
effects were not identical for protein IX-positive and protein IX-
negative particles, making the results obtained with these particles in
comparative binding assays unreliable. Alternative protocols for
ﬂuorescent- or radio-labeling of vector particles might be more
suitable for comparing the cell-binding afﬁnity. Labeled vector
particles might also be used for analyzing differences in cell surface
motility between protein IX-containing and protein IX-lacking
vectors. Through largely unknown mechanisms HAdV-5 particles
migrate on the cell surface and alterations in viral movement can
result in modiﬁed transduction (Patterson and Russell, 1983).
The removal of the protein IX gene from a replication-competent
HAdV-5 virus results in a small-plaque phenotype on CAR-positive
as well as CAR-negative cell lines. This suggests the tropism
modifying mutation affects the virus's capacity to spread from cell
to cell. Such small-plaque phenotypes of extended tropism mutants
is not unprecedented: similar phenotypes have been described for
murine corona virus mutants that acquired the capacity to bind
heparin (de Haan et al., 2005).
To investigate the effect of protein IX-gene deletion on the
interaction of HAdV-5 with human mononuclear leukocytes, we
compared the vectors Ad5ΔE1+pIX and Ad5ΔE1ΔpIX for GFP
expression in PBMCs. Flow cytometry analyses demonstrated GFP
expression almost exclusively in monocytes, with similar expression
levels for both vectors. However, increased activation of the entire
monocyte population (so not exclusively restricted to the GFP-
positive population) was observed for Ad5ΔE1ΔpIX, as demonstrated
by an enhancement in CD86 expression. CD86 is an activation marker
on antigen-presenting cells such as monocytes, macrophages, den-
dritic cells, and B cells, and is important for co-stimulation of T cells
(Reiser and Stadecker, 1996). The increased activation of monocytes
despite similar levels of transduction (GFP expression) could be due to
a direct effect on the monocytes themselves or indirectly via a more
efﬁcient stimulation of T cells or NK cells. Uptake of the protein IX-
deleted vector may be increased and/or may follow different
intracellular trafﬁcking routes (Drouin et al., 2010; McNees et al.,
2004). As a consequence, more efﬁcient viral antigen loading onto
human leukocyte antigen (HLA) molecules, or an increase in CD86
expression, could lead to more T cell activation, and e.g. IFN-γ
secretion. Of note, most healthy adult donors have HAdV speciﬁc T
cells (Heemskerk et al., 2003). Indeed, Ad5ΔE1ΔpIX incubationresulted in enhanced production of IFN-γ. Protein IX-gene deletion
appeared to affect NK cell activation as well, resulting in increased
expression levels of CD69, which is an activation marker for
lymphocytes including NK cells (Cambiaggi et al., 1992). Increased T
cell activation could have been accompanied by increased levels of
other T cell cytokines like interleukin-2 (IL-2). IL-2 is a known
activating cytokine of NK cells (He et al., 2004; Trinchieri et al., 1984).
Alternatively, the increased production of IFN-γ in the supernatant
would also be consistent with increased activation of NK cells by the
vector lacking pIX, without the involvement of T cells.
Irrespective of the mechanism, the increased activation of
monocytes and NK cells as a result of protein IX deletion is likely to
have important consequences for the in vivo implementation of
protein IX modiﬁed HAdV-5 vectors, since monocytes (after differ-
entiation to Kupffer macrophages in the liver) as well as NK cells are
important players in the sequestration of HAdV-5 vectors from the
blood after systemic delivery (reviewed in Muruve, 2004). Further-
more, the observed differences in PBMC activation between Ad5ΔE1+
pIX and Ad5ΔE1ΔpIX suggest a biological function of protein IX in
diminishing the immune response against HAdV-5. Further studies
will be necessary to fully determine the effects of protein IX deletion
from HAdV-5 on the activation of immune cells.
Omission of protein IX from the capsid resulted in a remarkable
difference between Ad5ΔE1+pIX and Ad5ΔE1ΔpIX upon intravenous
administration in mice. Administration of Ad5ΔE1ΔpIX yielded more
than ten-fold higher luciferase activity in the liver, for reasons that
remain to be clariﬁed. Extensive research has been devoted to
deﬁning the molecular mechanisms behind the sequestration of
intravenously administered HAdV-5 in the human liver, with the aim
to eventually improve the therapeutic efﬁcacy of intravenously
delivered HAdV-5 vectors (reviewed in Di Paolo and Shayakhmetov,
2009). The uptake of HAdV-5 in the liver has been found to occur in a
CAR-independent manner and involves binding of the virus particles
in the blood to complement factors and immunoglobulins (mediating
uptake in Kupffer cell macrophages) (Kalyuzhniy et al., 2008; Xu et al.,
2008), and coagulation factors (resulting in hepatocyte transduction)
(Kalyuzhniy et al., 2008; Waddington et al., 2008). The enhanced
transduction of the liver with Ad5ΔE1ΔpIX observed in our mouse
model seems not to be a result of more efﬁcient binding of the vector
to coagulation factor X (FX), as can be concluded from our in vitro FX-
binding assay. An alternative explanationmight be that the absence of
protein IX extends the HAdV-5 tropism, enabling the transduction of
cells in the liver that do not present CAR. Of interest, primary human
hepatocytes were recently found to have CAR localized at cellular
junctions that are inaccessible to the hepatic blood ﬂow (Au et al.,
2007). This localization is in contrast to the CAR molecules on
hepatocellular carcinoma cells (like HepG2), being highly available for
HAdV-5 binding (Au et al., 2007; Bangari et al., 2005).
Protein IX is strongly conserved in all primate adenoviruses
indicating the importance of the protein. A biological role for protein
IX in HAdV-5 capsid stabilization has been proposed, based on in vitro
heat-stability assays (Vellinga et al., 2005a). Our ﬁndings point
toward other biological functions of protein IX in (i) determining the
cell tropism of HAdV-5, and (ii) negatively interfering with the innate
immune response against HAdV-5. More insight into the mechanisms
by which the presence of protein IX affects gene transfer and
activation of immune cells may be of use for enhancing the efﬁciency
of current (e.g. Atencio et al., 2006) and future gene therapies
involving protein IX modiﬁed HAdV-5 vectors.
Materials and methods
Cell lines
All cell lines were maintained as monolayers at 37 °C in a
humidiﬁed atmosphere of 5% CO2. The human cell lines HeLa (cervical
Table 1
Oligonucleotides used in the cloning procedures.
FWD CAR_PstI 5′-GATGTACTGCAGATGGCGCTCCTGCTGTG-3′
REV CAR_
NheI
5′-CGACGCTAGCTATACTATAGACCCATCCTTGCTCTG-3′
FWD
ScaI_correct
5′-TTGCAGCAGCCGCCGCCGCCAGTACTAGCACCAACTCGTTTGATGG-3′
REV
ScaI_correct
5′-CCATCAAACGAGTTGGTGCTAGTACTGGCGGCGGCGGCTGCTGCAA-3′
FWD
SpeI_correct
5′-GGTTTCTGCCCTGAAGGCTTACTAGTCTCCCAATGCGGTTTAAAAC-
3′
REV
SpeI_correct
5′-GTTTTAAACCGCATTGGGAGACTAGTAAGCCTTCAGGGCAGAAACC-3′
FWD
pIX_ScaI
5′-CGCGGAAGTACTATGAGCACCAACTCGTTTGATGG-3′
REV
pIX_SpeI
5′-CGCACTAGTTTAAACCGCATTGGGAGGGGAGG-3′
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MZ2-MEL3.0 (melanoma) (de Vrij et al., 2008), VH10 (primary
foreskin ﬁbroblasts) (Klein et al., 1990), HepG2 (hepatocellular
carcinoma), and 911 cells (HAdV-5 E1-transformed human embry-
onic retinoblasts) (Fallaux et al., 1996) were maintained in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) (Gibco-BRL, Breda, The
Netherlands) supplemented with 8% fetal bovine serum (FBS)
(Gibco-BRL, Breda, The Netherlands) and penicillin–streptomycin
mixture.
Lentivirus transduction was used to create a MZ2-MEL3.0 cell
line stably expressing human CAR. To this end, the CAR gene was
PCR-ampliﬁed by using primers 1 and 2 (Table 1) from plasmid
pCMV_hCAR (kindly provided by Dr. J.M. Bergelson et al., 1997).
The PstI+NheI digested PCR product was ligated in between the
corresponding restriction sites of pLV.CMV.IRES.PURO (Uil et al.,
2009), resulting in pLV.CMV.CAR.IRES.PURO. The virus LV.CMV.CAR.
IRES.PURO was produced by a previously described procedure
involving cotransfection of pLV.CMV.CAR.IRES.PURO together with
‘helper’ plasmids encoding HIV-1 gag-pol, HIV-1 rev, and the VSV-
G envelope (Carlotti et al., 2004). The methods for determining the
titer of the LV.CMV.CAR.IRES.PURO vector stock and the procedures
for transduction of the MZ2-MEL3.0 cells have been described
before (Uil et al., 2009). Selection for antibiotic resistance was
achieved by seeding the cells in medium with 0.6 μg/ml puromycin
(MP Biomedicals, Amsterdam, The Netherlands).Viruses
The vectors HAdV-5.CMV.GFP/LUC (Vellinga et al., 2006)
(Ad5ΔE1+pIX) and HAdV-5ΔpIX.CMV.GFP/LUC (Vellinga et al.,
2006) (Ad5ΔE1ΔpIX) contain a green ﬂuorescent protein (GFP)
gene as well as a ﬁreﬂy luciferase (LUC) gene, which are both
driven by a human cytomegalovirus (CMV) promoter. The vector
HAdV-5pIXΔ100-114.CMV.LUC (Ad5ΔE1pIXΔLEU), encoding LUC
only, was described previously as well (Vellinga et al., 2005a).
Titration of the vector stocks was performed by a PicoGreen-DNA
binding assay to determine the concentration in physical vector
particles per ml (pp/ml) (Murakami and McCaman, 1999). A
standard agar overlay plaque assay on 911 cells was used to
determine the infectious virus concentration in plaque forming
units per ml (pfu/ml) (Fallaux et al., 1996). The pp/pfu ratios of the
three vectors were very similar, within the range of 10 to 12.
The replication-competent virusesHAdV-5.ΔE3.ADP.eGFP (Ad5+pIX)
and HAdV-5.ΔE3.ADP.eGFP.ΔpIX (Ad5ΔpIX) were constructed by recom-
bination of the shuttle plasmids pShuttle+E1+pIX (pSh+pIX) and
pShuttle+E1ΔpIX (pShΔpIX) with a HAdV-5 backbone plasmid
containing the eGFP gene in the E3 region (pBB). The plasmids pSh
+pIX, pShΔpIX and pBB were constructed as follows. The wild-typeHAdV-5 BsrGI–MfeI fragment containing the E1 genes (nucleotides
193–3925) was isolated from pTG3602 (kindly provided by Dr. M.
Luski, Transgene, Strasbourg, France), and cloned into the BsrGI–MfeI
digested pTrackCMV-GFP/LUC (Vellinga et al., 2006), thereby replacing
the GFP/LUC genes with the HAdV-5 E1 region. By using site-directed
mutagenesis (QuikChange site-directed mutagenesis kit; Stratagene)
(primers 3, 4, 5, 6; Table 1) two restriction sites were introduced in
the protein IX gene; a ScaI site at the start codon of protein IX and a
SpeI site upstream of the protein IX stop codon, thereby creating
pShuttle+E1+pIXScaI/SpeI. Next, the pShΔpIX plasmid was constructed
by ScaI/SpeI digestion and re-ligation of the protein IX-gene-deleted
fragment. The pSh+pIX plasmid was created by introducing the
protein IX sequence (ampliﬁed from pAd5pIX (Vellinga et al., 2004)
by using primers 7 and 8 (Table 1)) into the ScaI/SpeI linearized
pShuttle+E1+pIXScaI/SpeI. The ScaI site was restored to thewild-type
HAdV-5 sequence by exchanging the ScaI-overlapping MfeI/HindIII
fragment with the corresponding fragment from pTG3602. The SpeI
site and the downstream ‘pIX-remainder sequence’ were left intact,
since part of this sequence forms a hairpin-loop structure situated
over the polyA site of the E1B transcript, whichmight be essential for
efﬁcient polymerase slippage needed for polyadenylation (Sittler et
al., 1995).
The pBB backbone plasmid was constructed by replacing the E3-
lacking SpeI–PacI fragment (nucleotides 27238–33443) of pAdEasy-1
(He et al., 1998) with the corresponding SpeI–PacI fragment of
pShuttle-ΔE3-ADP-EGFP-F2 (Ono et al., 2005), thereby introducing
eGFP in the E3 region under control of the viral major late promoter.
The coding sequence for the E3 Adenovirus Death Protein (ADP) was
retained. The kanamycin resistance gene (inserted with the pShuttle-
ΔE3-ADP-EGFP-F2 fragment) was removed by ClaI digestion and re-
ligation of the two largest fragments.
Recombination of pBB with pSh+pIX and pShΔpIX in E. coli
and subsequent virus rescue in A549 cells were performed as
described elsewhere (He et al., 1998). Virus was puriﬁed by a
standard double cesium chloride gradient protocol, dialyzed
against sucrose buffer (5% sucrose, 140 mM NaCl, 5 mM Na2-
HPO4.2H2O, 1.5 mM KH2PO4) and stored at −80 °C. The virus titer
was determined by the PicoGreen-DNA binding assay (Murakami
and McCaman, 1999) (for pp/ml measurement), and a plaque
assay on A549 cells (Fallaux et al., 1996) (for pfu/ml measure-
ment). For analysis of virus spread, GFP-positive plaques were
photographed (Olympus Camedia Digital Camera C-3030, installed
on an Olympus CK40 microscope) and the plaque size was
determined in arbitrary units (Olympus DP-soft v.5.0 Soft imaging
System software). The median plaque size of Ad5ΔpIX was
normalized to the plaque size for Ad5+pIX.
Analysis of CAR presentation on the cell surface
Flow cytometry was performed to determine the levels of CAR
presentation on the cell surface. Cells in suspension (in PBS with 0.5%
bovine serum albumin and 0.02% sodium azide) were incubated with
mouse monoclonal anti-CAR antibody (clone RmcB, Upstate Biotech-
nology, Lake Placid, NY, diluted 1:1000) for 30 min on ice, followed by
incubation with phycoerythrin (PE)-conjugated rabbit-anti-mouse
secondary antibody (Caltac Laboratories, Burlingame, CA, USA) for
30 min on ice. Flow cytometry data were analyzed with CellQuest
software (Becton Dickinson).
Immunohistochemistry was performed on the cell line MZ2-
MEL3.0/CAR. After washing with phosphate-buffered saline (PBS), the
cells were ﬁxed in acetone/methanol (1:1) for 10 min at room
temperature. Staining was performed with the anti-CAR antibody
(clone RmcB, Upstate Biotechnology, Lake Placid, NY, diluted 1:500).
Fluorescein isothiocyanate (FITC)-conjugated rabbit-anti-mouse an-
tibody (Jackson ImmunoResearch, France) was used as secondary
antibody.
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Luciferase expression
The transduction efﬁciency of CAR-positive (HeLa, A549, MEL2A,
MZ2-MEL3.0/CAR) and CAR-negative (MZ2-MEL3.0, VH10) cell
lines by Ad5ΔE1+pIX and Ad5ΔE1ΔpIX was compared by
measuring luciferase expression. Transduction was performed in
triplicate in 24-well plate wells in 500 μl DMEM/8% FBS. After a
two-hour incubation the virus-containing medium was replaced
with fresh medium without virus. At 24 h post transduction the
cells were washed once with PBS and lysed in 100 μl LUC–lysis mix
(25 mM Tris–phosphate (pH 7.8), 2 mM CDTA, 2 mM DTT, 10%
glycerol and 1% Triton-X in PBS). Luciferase production was
determined with the Promega Luciferase Assay by adding 25 μl
luciferase assay reagent to 10 μl lysate. Light intensity measure-
ment was performed in a Victor Wallac 2 microplate reader
(PerkinElmer, Inc., Waltham, MA, USA).
Integrin blocking
Indirect blocking of integrin-mediated virus uptake was per-
formed by incubating cells with EDTA. MZ2-MEL3.0 cells were
harvested from semi-conﬂuent tissue culture plates, washed three
times in PBS with 5 mM EDTA, and resuspended in standard PBS or
PBS supplemented with 0.9 mM CaCl2 and 0.5 mM MgCl2 (PBS++).
The Ad5ΔE1+pIX and Ad5ΔE1ΔpIX stocks were adjusted to equal pp
concentrations by adding sucrose buffer and were diluted 1:1 in a
5 mM EDTA solution in PBS. Virus (100 pp/cell) was added to 500,000
cells in 1 ml PBS or PBS++ and incubation was performed for 60 min
at 37 °C under constant agitation. Subsequently, the cells were
pelleted by centrifugation, dissolved in 5 ml medium and transferred
to 24-well plate wells (500 μl per well). Cells were incubated for 24 h
and analyzed for GFP expression by ﬂow cytometry. Data were
analyzed with CellQuest software (Becton Dickinson).
The anti-human CD51/61 monoclonal antibody (MAb LM609), an
αVβ3 integrin antagonist, andMAb P1F6, anαVβ5 integrin antagonist
(both obtained from Millipore) were used to test the inhibitory effect
of anti-integrin antibodies on virus transduction. Cells grown as
monolayers were pre-incubated with medium only or with medium
containing integrin function-blocking MAbs (10 mg/ml). After 30 min
of incubation, the excess antibody was removed by gentle washing
followed by virus transduction (100 pp/cell). Reporter gene expres-
sion was measured 24 h post transduction by performing a standard
luciferase assay.
Virus incubation with coagulation factor X (FX)
HepG2 and A549 cells were plated in 24-well plate wells. After a
PBSwash step, Ad5ΔE1+pIX or Ad5ΔE1ΔpIX (100 pp/cell) was added
in serum-free medium containing 8 μg/ml Factor X (FX) (HCX-0050,
Haemotologic Technologies Inc.), 8 μg/ml Gla-domainless Factor X
(FXMUT) (HCX-GD, Haemotologic Technologies Inc.) or no FX/FXMUT.
After 2 h the medium was replaced by normal medium. Luciferase
expression was measured 24 h post transduction.
Immunoblot analysis and electron microscopy
Immunoblot analyses were performed to assess the incorporation
of proteins into the capsid of Ad5ΔE1+pIX and Ad5ΔE1ΔpIX. The
western blotting and detection procedures were described previ-
ously (de Vrij et al., 2008). Virus lysates were prepared by adding
5×109 virus particles directly to western sample buffer. Capsid
proteins were visualized with rabbit polyclonal anti-protein IX
serum (1:2000) (Caravokyri and Leppard, 1995), goat polyclonal
anti-hexon (1:1000, ab19998, Abcam, Cambridge, UK), and mouse
monoclonal anti-ﬁber (1:5000, 4D2, Abcam) (Hong and Engler,
1991). Secondary antibodies were horseradish peroxidase (HRP)-conjugated goat-anti-rabbit and rabbit-anti-mouse (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA).
Electron microscopy was performed on Ad5ΔE1+pIX and
Ad5ΔE1ΔpIX samples adsorbed into glow-discharged carbon coated
copper grids and negatively stained for 30 s with 2% phosphotungstic
acid (pH 7). The viruses were examined with a FEI Tecnai Spirit
BioTwin transmission electron microscope operating at 120 kV.
Images were recorded on a 4 k×4 k Eagle CCD camera.PBMC analysis
Buffy coats were obtained from healthy donors after consent
(Sanquin Bloodbank, Leiden, The Netherlands) and centrifuged on a
Ficoll gradient to obtain PBMC. PBMC (1×106) were added to a well of
a 24-well plate in 0.5 mlmedium (RPMI/10%FCS) and virus was added
at the indicated MOI in 0.5 ml medium. After incubation at 37 °C and
5% CO2 for two days, the supernatants were isolated for interferon
gamma (IFN-γ) measurement, and the cells were prepared for ﬂow
cytometry analysis. Cells were washed twice with PBS/0.02% sodium
azide, ﬁxed for 10 min in 4% paraformaldehyde, washed twice with
PBS/0.5% BSA/0.02 sodium azide, and stained with antibodies.
Antibodies used were anti-CD3-PerCP-Cy5.5, anti-CD4-PE, anti-
CD14-APC, anti-CD14-PerCP-Cy5.5, anti-CD19-PE, anti-CD19-PerCP-
Cy5.5, anti-CD69-PE and anti-CD86-PE (Becton Dickinson, Franklin
Lakes, NJ, USA), anti-CD8-APC and anti-CD56-APC (Beckman Coulter,
Brea, CA, USA). Activation of NK cells was evaluated as increased CD69
expression on CD3−, CD14−, CD19−, CD56+ cells. Monocyte
activation was analyzed as increased CD86 expression on CD3−,
CD19−, CD14+ cells. Fluorescence was measured by ﬂow cytometry
on a FACS Calibur (Becton Dickinson) and data were analyzed with
CellQuest software (Becton Dickinson). IFN-γ in supernatants was
measured by ELISA using the PeliPair reagent set for human IFN-γ
(Sanquin, Amsterdam, NL).Viral distribution after intravenous delivery
Ad5ΔE1+pIX or Ad5ΔE1ΔpIX (109 pp) was injected in the tail
vein of 6-week-old athymic nude mice (NMRI nu/nu; Taconic M&B
A/S, Ry, Denmark), followed by sacriﬁcing the animals and
harvesting of multiple organs at 3 days post injection. Four hours
before Ad5ΔE1+pIX and Ad5ΔE1ΔpIX injection, pre-dosing was
performed with the empty vector HAdV-5.CMV (replication-
deﬁcient and not encoding a transgene) (5×1010 pp) to saturate
Kupffer cell macrophages. Tissue samples from each organ were
lysed in LUC–lysis mix and the luciferase expression was measured
according to the Promega Luciferase Assay. The protein concentra-
tion in the lysates was determined by using the bicinchoninic acid
protein assay (Pierce, Perbio Science BV, Etten-Leur, The
Netherlands), enabling the calculation of luciferase expression per
total protein. The experiment was performed under the Dutch
Experiments on Animals Act that serves the implementation of
“Guidelines on the protection of experimental animals” by the
Council of Europe (1986), Directive 86/609/EC, and only after a
positive recommendation by the Animal Experiments Committee.Acknowledgments
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